Burney Co. Sells 383 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Burney Co. trimmed its holdings in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 1.8% in the first quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 21,219 shares of the specialty pharmaceutical company’s stock after selling 383 shares during the quarter. Burney Co.’s holdings in Supernus Pharmaceuticals were worth $724,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently bought and sold shares of the stock. Assenagon Asset Management S.A. bought a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth about $1,049,000. Trust Point Inc. acquired a new stake in Supernus Pharmaceuticals in the 4th quarter valued at $325,000. China Universal Asset Management Co. Ltd. lifted its position in Supernus Pharmaceuticals by 350.7% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 6,314 shares of the specialty pharmaceutical company’s stock worth $183,000 after buying an additional 4,913 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in shares of Supernus Pharmaceuticals by 3.8% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 23,809 shares of the specialty pharmaceutical company’s stock worth $689,000 after buying an additional 872 shares during the last quarter. Finally, Louisiana State Employees Retirement System bought a new position in shares of Supernus Pharmaceuticals in the 4th quarter valued at about $790,000.

Supernus Pharmaceuticals Stock Performance

SUPN traded down $0.79 on Friday, hitting $28.78. 452,599 shares of the company were exchanged, compared to its average volume of 455,328. The stock’s fifty day moving average is $27.70 and its 200-day moving average is $29.32. Supernus Pharmaceuticals, Inc. has a 12 month low of $21.99 and a 12 month high of $35.44.

Insider Transactions at Supernus Pharmaceuticals

In related news, insider Tillotson Martin Tami 2,900 shares of the business’s stock in a transaction on Tuesday, July 30th. The was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 8.76% of the company’s stock.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.